Key facts
- Comanche Biopharma’s last known valuation is $210.0M (Oct 2025).
- It has raised $136.1M across 2 recorded rounds; the latest was Early Stage VC ($37.5M) in Dec 2023.
- Notable investors include GV, New Enterprise Associates, F-Prime Capital, Atlas Venture, Broadview Ventures — 8 tracked in total.
- Comanche Biopharma has filed 2 Form Ds with the SEC since 2023, most recently Jan 2024 ($37.5M sold to 7 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for Comanche Biopharma
Funding rounds
2 roundsAbout Comanche Biopharma
Operator of a biopharmaceutical company intended to develop an investigational siRNA medicine for preterm preeclampsia. The company provides access to evidence-based and affordable therapies for treating life-threatening complications of pregnancy, enabling women to avail themselves of cost-effective and sustainable preeclampsia treatment at its root cause.
- Sector
- Healthcare
- HQ
- Concord, MA, United States
- Founded
- 2020
- Employees
- 29
- Website
- comanchebiopharma.com/
- Ownership
- Privately Held (backing)
Comanche Biopharma doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Comanche Biopharma shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Comanche Biopharma in its N-PORT filings yet. We sweep new filings monthly.